Published in Trends Immunol on September 21, 2011
Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13
Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol (2012) 1.50
High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS One (2015) 1.45
Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 1.30
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest (2015) 1.27
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe (2013) 1.13
High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination. Clin Immunol (2014) 1.12
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe (2016) 1.09
AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog (2012) 1.07
Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med (2015) 1.06
Vaccines: from empirical development to rational design. PLoS Pathog (2012) 1.01
To dream the impossible dream: universal influenza vaccination. Curr Opin Virol (2013) 0.98
Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano (2013) 0.97
Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci (2015) 0.95
Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins. Vaccine (2012) 0.93
Emerging roles for protein S-palmitoylation in immunity from chemical proteomics. Curr Opin Chem Biol (2013) 0.92
High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J Virol (2015) 0.90
Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene. J Virol (2014) 0.90
Modeling Influenza Virus Infection: A Roadmap for Influenza Research. Viruses (2015) 0.84
Novel viral vectored vaccines for the prevention of influenza. Mol Med (2012) 0.83
Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay. Viral Immunol (2014) 0.83
Cutting edge: Expression of FcγRIIB tempers memory CD8 T cell function in vivo. J Immunol (2013) 0.81
Fast vaccine design and development based on correlates of protection (COPs). Hum Vaccin Immunother (2014) 0.77
Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol (2016) 0.77
Immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza A virus. Biologics (2013) 0.75
Vaccine efficacy and T helper cell differentiation change with aging. Oncotarget (2016) 0.75
Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses. J Virol (2016) 0.75
Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. Front Immunol (2017) 0.75
A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques. PLoS One (2017) 0.75
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature (1988) 8.32
Activation of influenza A viruses by trypsin treatment. Virology (1975) 8.07
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86
Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A (1982) 7.34
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Influenza pandemics of the 20th century. Emerg Infect Dis (2006) 7.19
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology (1975) 6.90
Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J Immunol (1967) 6.41
A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol (1993) 6.26
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature (1983) 5.56
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell (1985) 4.84
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
Influenza vaccine: the challenge of antigenic drift. Vaccine (2007) 4.23
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J (1992) 3.21
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol (2007) 3.00
Studies on the primary structure of the influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1975) 2.88
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A (2010) 2.59
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Effect of neuraminidase antibody on Hong Kong influenza. Lancet (1973) 2.11
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
Antibody-mediated modulation of immune responses. Immunol Rev (2010) 1.84
Influenza A virus neuraminidase limits viral superinfection. J Virol (2008) 1.79
Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis (2009) 1.64
Vaccination in the elderly: an immunological perspective. Trends Immunol (2009) 1.60
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A (2010) 1.42
Influenza. Crit Care Med (2008) 1.39
Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res (2008) 1.30
Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun (2010) 1.30
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Composition and functions of the influenza fusion peptide. Protein Pept Lett (2009) 1.27
A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res (2010) 1.07
Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res (1998) 1.04
2009 H1N1 influenza pandemic: field and epidemiologic investigations in the United States at the start of the first pandemic of the 21st century. Clin Infect Dis (2011) 1.00
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J (2010) 0.91
CDC names H1N1 vaccine priority groups. JAMA (2009) 0.84
Structural basis of antigenic variation: studies of influenza virus neuraminidase. Immunol Cell Biol (1992) 0.83
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc (2009) 3.30
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat Biotechnol (2013) 2.81
Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci Transl Med (2013) 2.71
Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells. J Clin Invest (2004) 2.21
Mature B cells class switched to IgD are autoreactive in healthy individuals. J Clin Invest (2007) 2.18
Comparison of lateral fabellar suture and tibial plateau leveling osteotomy techniques for treatment of dogs with cranial cruciate ligament disease. J Am Vet Med Assoc (2013) 2.04
Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest (2011) 1.94
Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med (2008) 1.88
Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. J Exp Med (2005) 1.85
Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol (2012) 1.74
Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med (2013) 1.47
High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med (2012) 1.44
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest (2015) 1.27
Human B cell subsets. Adv Immunol (2008) 1.25
Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol (2011) 1.21
Rapid generation of rotavirus-specific human monoclonal antibodies from small-intestinal mucosa. J Immunol (2010) 1.19
Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One (2012) 1.17
Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol (2014) 1.16
Most influenza a virions fail to express at least one essential viral protein. J Virol (2013) 1.14
Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest (2016) 1.12
Igkappa allelic inclusion is a consequence of receptor editing. J Exp Med (2007) 1.11
Cutting edge: Transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus. J Immunol (2007) 1.10
Diagnostic imaging in veterinary dental practice. Chronic endodontic disease of the right mandibular first molar tooth. J Am Vet Med Assoc (2011) 1.07
Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann N Y Acad Sci (2013) 0.96
Report of the 2011-2012 AACP Professional Affairs Committee: addressing the teaching excellence of volunteer pharmacy preceptors. Am J Pharm Educ (2012) 0.93
Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells. J Immunol (2013) 0.91
Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine (2012) 0.91
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol (2014) 0.91
Subatmospheric pressure dressing as a bridge to free tissue transfer in the treatment of open tibia fractures. Plast Reconstr Surg (2008) 0.90
Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjögren's syndrome with a special emphasis on BAFF. J Clin Immunol (2004) 0.88
Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. Immunobiology (2012) 0.87
The anergic B cell. Blood (2010) 0.87
Exploiting human memory B cell heterogeneity for improved vaccine efficacy. Front Immunol (2011) 0.85
Harnessing the immune system's arsenal: producing human monoclonal antibodies for therapeutics and investigating immune responses. F1000 Biol Rep (2011) 0.85
Root shock revisited: perspectives of early head start mothers on community and policy environments and their effects on child health, development, and school readiness. Am J Public Health (2008) 0.84
Global analysis of B cell selection using an immunoglobulin light chain-mediated model of autoreactivity. J Exp Med (2012) 0.83
In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza a virus nucleoprotein. Clin Vaccine Immunol (2013) 0.82
Neurocognitive function in HIV-infected patients with low weight and weight loss. J Acquir Immune Defic Syndr (2003) 0.80
Inside Maine's Medicine Cabinet: Findings From the Drug Enforcement Administration's Medication Take-Back Events. Am J Public Health (2015) 0.79
"Come and take a walk": listening to Early Head Start parents on school-readiness as a matter of child, family, and community health. Am J Public Health (2005) 0.79
Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation (2014) 0.78
Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathog (2016) 0.78
Toxicity and bioaccumulation of biosolids-borne triclosan in food crops. Environ Toxicol Chem (2012) 0.77
(In)visible threats? The third-person effect in perceptions of the influence of Facebook. Cyberpsychol Behav Soc Netw (2011) 0.77
Sex differences on the judgment of line orientation task: a function of landmark presence and hormonal status. Physiol Behav (2011) 0.76
Corrigendum: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc (2014) 0.75
Endocrine-disrupting compounds in reclaimed water and residential ponds and exposure potential for dislodgeable residues in turf irrigated with reclaimed water. Arch Environ Contam Toxicol (2015) 0.75